FDA Approves Celgene's Supplemental New Drug Application for Pancreatic Cancer Treatment

The FDA has approved Celgene's supplemental new drug application for ABRAXANE, a pancreatic cancer treatment.
In combination with gemcitabine, ABRAXANE is a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, which accounts for about 95 percent of all pancreatic cancers.

The approval is based on results from the Metastic Pancreatic Adenocarcinoma Clinical Trial, a randomized, international study.

More Articles on Gastroenterology:
Drs. Renjy Vattasseril, Anthony Masciarelli Join Cape Regional Physicians Associates
NIH Grants Medical College of Wisconsin $2M to Study GERD
Probiotics May Not Prevent Crohn's Disease Relapses, Study Says

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast